Pentixapharm Holding AG Reduces Projected Loss for 2025

Pentixapharm Holding AG, a biotech company specializing in radiopharmaceuticals, announced a significant reduction in its projected financial loss for 2025. The new forecast estimates a loss of approximately €18 million, down from a previously anticipated €23.5 million.

This revision follows a realignment of the company's clinical development programs initiated in May 2025. The early termination of a slow-recruiting study in marginal zone lymphoma and optimized study designs have contributed to lower than expected clinical spending. The company is focusing on the most valuable clinical programs as part of its strategic optimization efforts.

Despite the reduction in projected losses, forecasts for the company's separate financial statements and expected cash reach until early 2027 remain unchanged.